- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05030246
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
A Phase Ⅱ, Single-arm Study to Evaluate the Efficacy and Safety of Surufatinib Combined With Toripalimab in Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Lin Shen, MD
- Telefonnummer: 86-10-88196561
- E-Mail: linshenpku@163.com
Studienorte
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Rekrutierung
- Beijing Cancer Hospital
-
Kontakt:
- Lin Shen, MD
- Telefonnummer: 86-10-88196561
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histologically or cytologically confirmed advanced peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer
- Failed after standard treatment
- Have evaluable lesions, including those that are not measurable
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- Adequately understand the study and voluntarily sign the Informed Consent Form;
- ≥18 years old;
- Lab tests within 7 days before first dose:
1) Absolute neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L, and hemoglobin ≥100g/L; 2) Serum total bilirubin ≤1.5 times the upper limit of normal (ULN); 3) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤2.5 times the ULN; 4) Patients without anticoagulant therapy: International Normalized Ratio (INR) ≤1.5 ULN and activated partial thromboplastin time (APTT) ≤1.5 ULN. If patients received anticoagulant therapy: INR ≤2 ULN and APTT was within the normal range 14 days before treatment; 5) Serum total bilirubin <1.5 times the upper limit of normal (ULN); 6) Urine protein < 2+; if ≥2+, 24-hour urine protein <1 g; 8. Male or females patients with reproductive potential must agree to use an effective contraceptive method, for example, double-barrier device, condom, oral or injected birth control medication or intrauterine device, during the study and within 90 days after study treatment discontinuation. All female patients are considered to be fertile, unless the patient had natural menopause or artificial menopause or sterilization (such as hysterectomy, bilateral oophorectomy or ovarian irradiation).
Exclusion Criteria:
- Prior system treatment with antiPD1/PDL1/PDL2/CTLA-4 antibody or Sulfatinib;
- Previous intraperitoneal treatment with immunologic agents;
- Patients with digestive tract obstruction or uncontrolled active bleeding from the primary tumor;
- Patients with any active autoimmune disease or a documented history of autoimmune disease: Patients with hypothyroidism but receiving a stable dose of thyroid hormone replacement therapy were included in the study, and subjects with stable type 1 diabetes were able to control their blood sugar;
- Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severe impaired lung function, etc;
- Prior major surgery within past 4 weeks and had not fully recovered from previous surgery;
- Active bleeding or abnormal coagulation, Prone to bleeding or receiving thrombolytic or anticoagulant therapy;
- Hypertension that is not controlled by the drug, and is defined as: SBP≥140 mmHg and/or DBP≥90 mmHg;
- Prior antitumor therapy (including chemotherapy, immunotherapy, biological treatment, Targeted therapy, etc) , or have not recovered from toxicities since the last treatment;
- Pregnant or nursing;
- previously received allogeneic stem cell or parenchymal organ transplantation;
- Any significant clinical or laboratory abnormality that the investigator considers to influence the safety evaluators;
- History of uncorrected serum electrolyte disturbances such as potassium, calcium, or magnesium;
- Known human immunodeficiency virus (HIV) infection;
- Active hepatitis B virus (HBV) and hepatitis C virus (HCV) infected persons;
- A history of other malignancies within 5 years prior to inclusion, except for cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery;
- Prior treatment with corticosteroids (dose > 10 mg/day prednisone or other hormones) or other immunosuppressive agents within 2 weeks, nasal or inhalation in allowed (dose > 10 mg/day prednisone or other hormones);
- Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, LVEF <50%, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
- History with tuberculosis who are receiving or have received anti-TB treatment within 1 year;
- Active infection;
- Receiving another experimental drug or participating in a clinical study for another therapeutic purpose within the first 28 days prior to treatment initiation;
- Any other disease, metabolic disorder, abnormal results of a physical examination or laboratory examination, and reasonably suspected disease or condition that may contraindication the use of the investigational drug, or affect the reliability of the study results, or place the patient at high risk for treatment complications, or affect patient compliance.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Surufatinib 250mg/Toripalimab 240mg
Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody(Toripalimab) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
|
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Survival (OS)
Zeitfenster: From date of first dose of study drug until withdrawal of consent or death (up to approximately 1 year)
|
Duration from the date of initial treatment with Surufatinib plus toripalimab to the date of death due to any cause.
|
From date of first dose of study drug until withdrawal of consent or death (up to approximately 1 year)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-free Survival (PFS)
Zeitfenster: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 1 year)
|
A duration from the date of initial treatment with Surufatinib combined with Toripalimab to disease progression or death of any cause.
|
From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 1 year)
|
adverse events
Zeitfenster: 1 year
|
Adverse events assessments are computed and categorized according to the Common Toxicity Criteria of the National Cancer Institute, version 5.0
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2021-012-CH04 IIT-GI
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Primärer Peritonealkrebs
-
University Hospital Inselspital, BerneAbgeschlossenRandomisierte, kontrollierte Studie | Ventrikulärer Peritoneal-Shunt | Shunt-Komplikationen | Shunt-FehlerSchweiz
-
CHU de ReimsAbgeschlossen
-
Association Francaise de ChirurgieAbgeschlossenWirkung des PIPAC auf die Überlebensrate von Patienten mit Peritonealkarzinose gastrischen UrsprungsKarzinomatose, PeritonealFrankreich
-
Fondazione Policlinico Universitario Agostino Gemelli...Istituto Di Ricerche Farmacologiche Mario Negri; Foundation MedicineRekrutierungFortgeschrittener (Stadium IIIB-C-IV) Eierstock-, primärer Peritoneal- und EileiterkrebsItalien
-
Jules Bordet InstituteAbgeschlossen
-
University Hospital, GhentRekrutierungEierstockkrebs | Darmkrebs | Bauchspeicheldrüsenkrebs | Karzinomatose, PeritonealBelgien
-
AstraZenecaRUSSCO (Russian Society of Clinical Oncology)AbgeschlossenEierstock-, Peritoneal- und Eileiterkrebs, BRCAm+ in RusslandRussische Föderation
-
National Cancer Institute (NCI)NRG OncologyAktiv, nicht rekrutierendOvariales seromuzinöses Karzinom | Rezidivierendes hochgradiges seröses Adenokarzinom der Eierstöcke | Rezidivierendes platinresistentes Ovarialkarzinom | Muzinöses Adenokarzinom des Eileiters | Rezidivierendes klarzelliges Adenokarzinom des Eileiters | Rezidivierendes endometrioides Adenokarzinom... und andere BedingungenVereinigte Staaten, Puerto Rico
Klinische Studien zur Surufatinib/Toripalimab
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutierung
-
Hutchison Medipharma LimitedAbgeschlossenFortgeschrittene solide TumorenChina
-
Fujian Cancer HospitalNoch keine RekrutierungNasopharynxkarzinomChina
-
Fudan UniversityUnbekannt
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Noch keine Rekrutierung
-
Zhejiang UniversityRekrutierung
-
Sun Yat-sen UniversityRekrutierungKleinzelliges LungenkarzinomChina
-
Fudan UniversityNoch keine RekrutierungIntrahepatisches Cholangiokarzinom
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... und andere MitarbeiterNoch keine RekrutierungNeuroendokriner Tumor Grad 3
-
Qilu Hospital of Shandong UniversityNoch keine Rekrutierung